Bristol-Myers Squibb: Hodgkin Disease trials

The registry lists 12 Hodgkin Disease studies with Bristol-Myers Squibb as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 1 4Phase 2 6Phase 3 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin LymphomaTerminatedNCT05255601Phase 1/2Results posted
• A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,TerminatedNCT03138499Phase 3Results posted
• A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line TreatmentCompletedNCT02927769Phase 2Results posted
• Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)CompletedNCT02181738Phase 2Results posted
• An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple MyelomaCompletedNCT01592370Phase 1/2Results posted
• Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal FunctionCompletedNCT00652626Phase 1Results posted
• Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With NivolumabCompletedNCT03200977
• Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in MexicoWithdrawnNCT03161613
• Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology PracticesCompletedNCT02856646
• Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's LymphomaCompletedNCT00634452Phase 1
• Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's LymphomaTerminatedNCT00358982Phase 2
• A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's DiseaseCompletedNCT00284804Phase 2